Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc

E Roccato1, C Miranda1, V Ranzi1, M Gishizki2, MA Pierotti1 and A Greco⁎1

1 Department of Experimental Oncology, Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milan, Italy; 2 UGEN, 230 East Grand Ave, South San Francisco, California, CA 94080, USA

The thyroid TRK-T3 oncogene, produced by a chromosomal translocation, is a chimeric, constitutively activated version of the NTRK1/NGF receptor and it is able to transform NIH3T3 cells and differentiate PC12 cells. TRK-T3 oncoprotein triggers multiple signal transduction pathways. Among others, TRK-T3 binds and phosphorylates the Shc and SNT1/FRS2 adaptor proteins both involved in coupling the receptor tyrosine kinase to the mitogen-activated protein kinase pathway by recruiting Grb2/SOS. We were interested in defining the role of Shc in the oncogenesis by TRK-T3. The mutation of TRK-T3 tyrosine 291, docking site for both Shc and FRS2, abrogates the oncogene biological activity. To directly explore the role of Shc we used the ShcY317F mutant, which carries the mutation of a tyrosine residue involved in Grb2 recruitment. We demonstrated that the ShcY317F mutant exerts an inhibitory effect on TRK-T3 transforming activity. Such effect can be modulated by the amount of ShcY317F protein and affects the viability of cells expressing TRK-T3 by means of a mechanism involving apoptosis. Our results indicate a definitive role of the adaptor protein Shc in TRK-T3 transforming activity.

Keywords: TRK-T3; Shc; NTRK1; signal transduction; transforming activity
The involvement of Shc in NTRK1 signal transduction has been demonstrated by various studies (Obermeier et al., 1993; Stephens et al., 1994). In a previous work we detected interaction of Shc SH2 domain with the wild type NTRK1 receptor and various TRK oncogenes expressed in NIH3T3 cells (Borrello et al., 1994). After the subsequent discovery of the Shc PTB domain, experiments with PC12 cells showed that Shc PTB domain interacts with Tyr490 of the activated NTRK1 receptor, whereas the interaction with an unidentified p115 phosphoprotein was proposed for the SH2 domain (Dikic et al., 1995).

As we are interested in elucidating the signal transduction pathways leading to the TRK oncogene transformation of NIH3T3 cells, we began by investigating the involvement of the proteins known to transduce NTRK1 signals. This apparently obvious approach is not as trivial as it may seem because NGF-induced NTRK1 activation leads to cell type specific biological effects, such as the differentiation of neuronal cells, the apoptosis of medulloblastoma cells and the mitogenesis of non-neuronal cells (Muragaki et al., 1997). This suggests that the critical elements of NTRK1 signalling may vary in cell lines from different tissues. In addition to differences due to cell specificity, TRK oncogenes may trigger signal transduction pathways other than the wild type receptor as a consequence of the properties contributed by structural rearrangements (cytoplasmic localization, the presence of activating sequences).

In a previous study we demonstrated that Shc is activated by TRK oncoproteins and therefore capable to recruit Grb2 (Borrello et al., 1994). We have more recently also determined the activation of FRS2, PLCγ, ERK1/2 and JNK MAP kinases in cells transformed by TRK-T3 (Greco et al., manuscript in preparation), as well as the recruitment of IRS1 and IRS2 by NTRK1 and TRK-T1 oncogene (Miranda et al., 2001).

In the study reported here we investigated the contribution of the Shc adaptor in TRK-T3 signal transduction. The mutation of the docking site for both Shc and FRS2 abolished the TRK-T3 biological activity, thus indicating that possible other pathways might not overcome the lack of the two adaptors. To further define the role of Shc in TRK-T3 activity we used the ShcY317F dominant-negative mutant, in which one of the tyrosines recruiting the Grb2/SOS complex has been mutated to phenyalanine. Our data show that ShcY317F reduces TRK-T3 biological activity, thus indicating the indispensability of Shc. Moreover, we report evidences that cells expressing both TRK-T3 and ShcY317F undergo cell death by a mechanism involving apoptosis.

MATERIALS AND METHODS

Plasmid construction

The T3/WT plasmid contains the TRK-T3 cDNA inserted into the pRC/CMV expression vector (Greco et al., 1995), which carries the neomycin resistance gene. The T3/Y291F mutant carries the mutation of Tyr291 to phenyalanine (F291) and was constructed by means of site-directed mutagenesis using an in vitro oligonucleotide mutagenesis system (Altered Sites Mutagenesis System, Promega). The T3/ABN kinase-defective mutant carries the mutation of the ATP binding site Lys339 to Ala (Greco et al., 1998). In ShcY317F mutant the Tyr317 is mutated to Phe. The cDNAs encoding ShcWT and ShcY317F are inserted in the pCGN expression vector, containing the hygromycin-resistance gene, and are tagged by the HA epitope at the N-terminus.

The VGF8-luc is a reporter plasmid made of vgf promoter sequence fused to the luciferase reporter gene (a kind gift from Dr R Possenti).

The pRL-CMV vector, containing the coding region of the Renilla luciferase (RL) gene, was provided by Promega.

Cell culture and transfection

Mouse NIH3T3 fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum, human kidney 293T cells in DMEM supplemented with 10% foetal calf serum, and transformed cell lines in DMEM supplemented with 5% calf serum. PC12 cells were grown in RPMI-1640 medium supplemented with 5% foetal calf serum and 10% horse serum. NF797 cells are NIH3T3 cells transformed by the TRK-T3 oncogene; NWT and NY317F cell lines are derived from NIH3T3 cells respectively transfected with ShcWT and ShcY317F plasmids, and selected in the presence of hygromycin (25 μg ml⁻¹). 3.9HG are semi-transformed cells generated by the transfection of NY317F cells with the TRK-T3 oncogene and isolated in medium supplemented with 5% calf serum plus hygromycin (25 μg ml⁻¹) and G418 (400 μg ml⁻¹).

The NIH3T3, NWT and NY317F cells (8 × 10⁴/160 mm plate) were transfected by the CaPO₄ method as previously described (Bongarzone et al., 1989), using 250 ng of expression plasmid DNA together with 15 μg of mouse DNA. Transformed foci were selected in DMEM supplemented with 5% serum, in the presence or absence of hygromycin (25 μg ml⁻¹), G418 (400 μg ml⁻¹) or both. G418- and hygromycin-resistant colonies were selected in DMEM plus 10% serum containing the selective agents at the above concentrations. The transformed foci and resistant colonies were either fixed or isolated for further studies 2 weeks after transfection. The 293T cells were transiently cotransfected with T3/WT or T3/ mutants (1 μg) together with Shc constructs or pCGN empty vector (5 μg) using the CaPO₄ method. The cells were kept in 10% serum medium for 6–7 h, serum-starved overnight in DMEM containing 0.5% FCS, and then processed for protein extraction.

PC12 cells were transfected using Cellfectin (Life technologies, Inc.). Cells (2 × 10⁶) were seeded on collagen-coated 12-multwell plates and transfected with 400 ng of T3/WT or T3/Y291F plasmid. In cotransfection experiments 100 ng of T3/WT together with 500 ng of ShcWT, ShcY317F or pCGN plasmid were used. Specific plasmid DNA were transfected together with 150 ng of VGF8-luc plasmid and 50 ng of pRL-CMV plasmid (Promega). Cells were incubated with the reagent for 7 h and scored for neurites outgrowth 2 days later.

Luciferase activity assay

Both luciferase activities of VGF8-luc and pRL-CMV genes in PC12 cells lysates were measured using the Dual-luciferase reporter assay system (Promega). Assays were performed according to the manufacturer's recommendations. Light emission was measured using a TD-20/20 Luminometer.

Microfocus forming assay

The assay was performed as described by Li et al. (1999). One hundred cells from NF797 cell lines transfected with pCGN vector, ShcWT or ShcY317F were combined with 1 × 10⁵ NIH3T3 cells in 10-cm dishes, and cultured for 2 weeks in medium containing 5% calf serum. The foci were counted after GIEMSA staining.

Immunoprecipitation, pull-down and Western blot analysis

Cells were lysed with PLCLB buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl₂, 1 mM EGTA, 10 mM Na₃PO₄, 100 mM NaF) supplemented with aprotinin, pepstatin, leupeptin, PMSF and Na₂VO₄. One milligram of the cell extracts was precipitated with the appropriated antibodies, or with GST-Grb2(SH2) fusion protein conjugated to glutathione-Sepharose, or with p13suc1-agarose. The precipitates were washed three times.
times with HNTG buffer (20 mM HEPES, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol) and boiled in Laemmli sample buffer. Protein samples were electrophoresed on 8.5% SD–PAGE; transferred onto nitrocellulose filters and immunoblotted with the appropriated antibodies. The immunoreactive bands were visualised using horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence (Amersham). The anti-TRK and anti-Grb2 antibodies were from Santa Cruz Biotech., Inc.; the anti-HA antibodies were from BabCo; the anti-FRS2, anti-phosphotyrosine antibodies and the p13suc1-agarose were from Upstate biotechnology, Inc.

TUNEL analysis of DNA fragmentation

In situ detection of apoptotic cells was performed on adherent cells cultured on chamber slides by using the In Situ Cell Death Detection Kit, Fluorescein (Boehringer Mannheim), according to the manufacturer’s instruction. The slides were then counterstained with 4',6-diamin2-phenylindole.

RESULTS

TRK-T3 biological activity requires the Shc/FRS2 docking site

The Tyr490 residue of the NTRK1 receptor is involved in the recruitment and activation of Shc adaptor proteins; such interaction occurs through the Shc PTB domain (Dikic et al., 1995). Tyr490 is also the docking site for SNT1/FRS2, a myristilated adaptor molecule signalling through Grb2/SOS/ERKs (Rabin et al., 1999). With the final aim to provide evidences of possible oncogene-specific signal transduction pathways that could bypass the need for Shc and FRS2, we defined the role of TRK-T3 Tyr291 (corresponding to NTRK1 Tyr490) in the oncogene biological activity. The tyrosine residue was changed to phenylalanine by site-directed mutagenesis, to produce T3/Y291F (Figure 1). Wild type and Y291F TRK-T3 cDNAs were inserted into the pRC/CMV expression vector. The Shc cDNAs contain the HA epitope at the N-terminus and were inserted into the pcGN mammalian expression vector.

Effect of ShcY317F mutant on TRK-T3-dependent signal transduction

As a tool for defining the role of Shc adaptor in TRK-T3 signal transduction we used the ShcY317F mutant of the 52 kDa Shc isoform (Figure 1), in which the tyrosine 317 has been changed to phenylalanine. Tyr317 of Shc, in addition to Tyr291F, recruits Grb2 upon phosphorylation; the ShcY317F mutant has been shown to exert a dominant-negative effect in different biological processes mediated by Shc (Li et al., 1999; Stevenson et al., 1999; Boney et al., 2000; Mercalli et al., 2001). The ShcY317F and the control ShcWT constructs (Figure 1) were tagged by the haemoagglutinin (HA) epitope, which confers a small electrophoretic shift with respect to the endogenous p52 Shc, and cloned into the pcGN expression vector harbouring the resistance to hygromycin.

We investigated the capability of ShcY317F to interact with TRK-T3 oncoprotein. Human kidney 293T cells were transiently cotransfected with TRK-T3 or T3/ABN kinase-dead mutant, together with HA-tagged ShcWT, ShcY317F or the pcGN vector as control (Figure 3). The expression of the transfected proteins is shown in Figure 3C. Similarly to ShcWT, the 53 kDa phosphorylated ShcY317F protein coprecipitated with TRK-T3, as shown by the anti-phosphotyrosine Western blot hybridisation of anti-TRK immunocomplexes. This interaction required the phosphorylation
of TRK-T3, as it was undetectable when the T3/ABN kinase-dead mutant (Greco et al., 1998) was used (Figure 3A).

We next investigated the ability of ShcY317F to recruit Grb2 upon TRK-T3 activation. The same cell extracts as above were incubated with the GST-Grb2(SH2) fusion protein, containing the Grb2 SH2 domain. Hybridisation with anti-HA antibodies (Figure 3B, top) showed that the amount of ShcY317F protein reacting with GST-Grb2(SH2) is lower than ShcWT, in accordance with the lack of an interaction site. The ShcY317F-Grb2 interaction was also investigated by coimmunoprecipitation experiments. The above cell extracts were immunoprecipitated with anti-Grb2 antibodies and hybridised with antiphosphotyrosine antibodies. Similarly to ShcWT and endogenous Shc proteins (data not shown), phosphorylated ShcY317F coprecipitated with Grb2 (Figure 3B, bottom). The ShcY317F-Grb2 interaction depends on the TRK-T3-triggered Shc activation, being undetectable when the T3/ABN kinase-dead mutant was used. Grb2 immunocomplexes also contain the phosphorylated TRK-T3 oncoprotein (Figure 3B, bottom), as consequence of both direct (MacDonald et al., 2000) and Shc/FRS2-mediated interaction. Altogether these results indicate that ShcY317F is phosphorylated by TRK-T3 at tyrosine residues 239/240 and therefore capable of recruiting Grb2.

As reported in the previous paragraph, both Shc and FRS2 bind, in a competitive manner, to phosphorylated NTRK1 Tyr490 residue (Meakin et al., 1999). We investigated the effect of ShcY317F on FRS2 activation induced by TRK-T3. The same cell extracts from serum-starved 293T cells transiently cotransfected with TRK-T3 and ShcWT, ShcY317F or the pCGN vector as control were pulldown with the FRS2-interacting p13suc1 protein conjugated to agarose beads, and the eluted complexes analysed by Western blot. As shown in Figure 3D, hybridisation with anti-phosphotyrosine antibodies detected comparable levels of FRS2 phosphorylation in cells expressing TRK-T3 in combination with the pCGN empty vector, ShcWT or the ShcY317F mutant. As control, the expression of FRS2 is shown. These results indicate that, in our experimental conditions, although in the presence of exogenous Shc proteins, Tyr291 of TRK-T3 is still capable to signal through FRS2.

Inhibitory effect of ShcY317F mutant on TRK-T3 biological activity

In the first paragraph we have shown that the biological activity of TRK-T3 is abrogated by the mutation of the Tyr291, docking site for Shc and FRS2. To directly explore the role of the Shc adaptor in
Role of Shc in TRK-T3 signalling

E Roccato et al

TRK-T3 signal transduction, we investigated the effect of the ShcY317F dominant-negative mutant on TRK-T3 biological activity. We first investigated the effect of ShcY317F on TRK-T3 differentiating activity. PC12 cells were cotransfected with TRK-T3 together with HA-tagged ShcWT, ShcY317F or the pCGN empty vector. The results are reported in Figure 4A. Three days after transfection cell transfected with TRK-T3 and ShcWT or pCGN displayed long neurites. On the contrary, cells transfected with TRK-T3 and ShcY317F showed shorter extensions, with a few of them exceeding the cell diameter. As control the expression of TRK-T3 and HA-tagged Shc proteins is reported (Figure 4A). The differentiating activity was measured by cotransfecting the VGF8-luc reported plasmid, as above described. Luciferase activity in cells expressing T3/WT and ShcY317F was reduced to 50% with respect to cells expressing T3/WT and ShcWT (graph in Figure 4A).

We next investigated the effect of ShcY317F mutant on TRK-T3 transforming activity. As first approach we performed the microfocus differentiation assay. NF797 cells (NIH3T3 transformed by the TRK-T3 oncogene) were transfected with ShcY317F and ShcWT or the empty pCGN vector as control, as described in Materials and Methods. Transfected cells were mixed with an excess of wild type NIH3T3 cells, seeded in medium containing 5% calf serum, and their ability to form foci was assessed. As shown in Figure 4A, focus formation capability was unaffected in the NF797 cells transfected with pCGN and ShcWT, but was reduced by about 50% in the cells expressing ShcY317F.

To more directly explore the effect of ShcY317F on TRK-T3 induced transformation we constructed NIH3T3 cell lines expressing exogenous ShcWT and ShcY317F proteins. The Shc constructs (Figure 1), as well as the pCGN empty vector, produced hygromycin-resistant NIH3T3 colonies with equivalent efficiency (data not shown), thus demonstrating that the overexpression of wild type and Y317F Shc proteins does not interfere with the growth of normal NIH3T3 cells. Several colonies were isolated and analysed for the expression of the transfected Shc constructs (data not shown). Selected cell lines (clone NWT for ShcWT and clone NY317F for ShcY317F) were used as recipients for focus formation assay. Both cell lines were transformed by Ha-ras and TRK-T3 oncogenes with comparable efficiency (data not shown).

However, whereas the Ha-ras foci displayed similar size in both recipient cell lines (data not shown), the foci induced by TRK-T3 in NY317F cells were smaller than those in NIH3T3 and NWT (Figure 4C). This difference is related to the inhibitory effect of ShcY317F rather than the growth rate of the NY317F parental cell line, as deduced by growth curve determination (unpublished observations).

In order to characterise further the inhibitory effect of ShcY317F on TRK-T3 transforming activity, we investigated the influence of the level of Shc mutant protein expression. To this aim we performed foci selection in the presence of hygromycin, whose resistance is carried by the pCGN expression vector, based on previous observations showing that the level of ShcWT and ShcY317F proteins increases when NWT and NY317F cells are cultured in the presence of the antibiotic (unpublished observations). As shown in Figure 4D, the addition of hygromycin did not affect the transforming activity of TRK-T3 in NWT cells. On the contrary, hygromycin reduced the number of foci induced by TRK-T3 in NY317F cells by about 60%, both in the presence and in the absence of G418, whose resistance is carried by the TRK-T3 expression vector. The presence of hygromycin also reduced the size of foci in NY317F cells (data not shown). These results support the view that ShcY317F exerts an inhibitory effect on TRK-T3 transforming activity, which can be modulated by the protein amount.

Long-term effects of ShcY317F on the TRK-T3 induced transformed phenotype

Having shown that ShcY317F reduced TRK-T3 transforming activity, we were interested in determining any long-term effect in foci
Figure 4  (A) Effect of ShcY317F on TRK-T3 induced PC12 differentiation. PC12 cells were cotransfected with TRK-T3 and ShcWT (a), ShcY317F (b) or pCGN (c) plasmids, together with VGF8-luc and Renilla plasmids, as described in Materials and Methods and scored for the presence of neurites 3 days later. As control, untreated (d) and NGF-stimulated (50 ng ml\(^{-1}\)) (e) PC12 cells are shown. After morphological analysis, transfected PC12 cells were lysates and subjected to immunoblot using anti-TRK and anti-HA antibodies to detect the level of transfected proteins. To quantify the TRK-T3 differentiating activity both luciferase activities were measured using the Dual-Luciferase reported assay system (Promega). The values were expressed relative to Renilla luciferase activity for normalisation. The results presented are an average of three experiments. (B) Microfocus formation assay. One hundred cells from focus NF797 (NIH3T3 cells transformed by TRK-T3 oncogene) transfected with pCGN vector, ShcWT or ShcY317F constructs were combined with 1 \(\times\) 10\(^5\) NIH3T3 cells in 10-cm dishes, and cultured for 2 weeks in medium containing 5% calf serum. The foci were counted after GIMSA staining. (C) Transforming activity of TRK-T3 in NIH3T3, NWT (NIH3T3 cells stably expressing ShcWT) and NY317F (NIH3T3 cells stably expressing ShcY317F) cells. Transfection and foci selection were performed as described in Materials and Methods. Foci and G418 resistant colonies were either fixed and GIMSA stained or isolated for further analysis after two weeks of selection. (D) Effect of hygromycin on TRK-T3 foci formation in NWT and NY317F cell lines. Foci selection was performed in 5% serum medium supplemented or not with 400 \(\mu g\) ml\(^{-1}\) of G418 (selectable marker contained in the TRK-T3 expression vector) in the absence or presence of 25 \(\mu g\) ml\(^{-1}\) hygromycin (selectable marker contained in the Shc expression vector). Foci were scored after 2 weeks of selection. For each cell line, the number of foci per \(\mu g\) DNA selected in the absence of hygromycin was set at 100%.
induced by TRK-T3 oncogene in NY317F cells, expressing the ShcY317F mutant. Several foci were isolated, in the presence or absence of hygromycin and/or G418 (as above reported, Figure 4D) with the aim of enhancing the expression of ShcY317F and/or TRK-T3 proteins. Interestingly, a difference was evident after isolation: the morphology of the TRK-T3 foci in NY317F cells was less transformed than that of the foci in NIH3T3 and NWT cells, and will be subsequently called ‘intermediate’ (Table 1). Soon after isolation (‘early’ in Table 1), Western blot analysis and/or immunofluorescence revealed that all the foci in NY317F cells expressed both TRK-T3 and ShcY317F proteins (data not shown). Later on the behaviour of the foci during culture varied according to the method of selection. The foci selected in the presence of hygromycin, which increased the level of ShcY317F protein, underwent a growth crisis starting 4 weeks after isolation. Most of the cells died; the surviving cells had a flat phenotype, and they could be rescued and propagated by increasing the serum concentration up to 10% (‘late’ in Table 1). At this stage Western blot and/or immunofluorescence analysis of the rescued cells showed loss of TRK-T3 expression, but no changes in ShcY317F expression. The same effect was observed in half of the foci isolated in the absence of selective agents, whereas the remaining 50% maintained the intermediate phenotype and the expression of TRK-T3 protein, but lost the expression of ShcY317F. The foci selected in the presence of both hygromycin and G418 maintained the intermediate phenotype and the expression of both TRK-T3 and ShcY317F proteins. Altogether these results indicate that TRK-T3 full transforming activity requires signaling through tyrosine 317 of Shc.

To get inside the cell death described above, the TRK-T3 induced NY317F foci were monitored twice a week for the occurrence of apoptosis by TUNEL. Although there was considerable variability among the clones, 2–10% of TUNEL-positive cells was detected in those undergoing a growth crisis and loosing TRK-T3 expression. By contrast, when the parental NY317F cell line or a NIH3T3 focus transformed by TRK-T3 were analysed, no TUNEL-positive cells were scored. Furthermore, the number of TUNEL-positive cells may have been underestimated because TUNEL picks up the late stage of apoptosis marked by DNA breaks. These results suggest that the inhibitory effect of ShcY317F on TRK-T3 transforming activity involves apoptosis.

The effect of selective agents on the transformed phenotype and ShcY317F and TRK-T3 protein expression was recapitulated on focus 3.9HG, which was selected and expanded in the presence of both hygromycin and G418, and had an ‘intermediate’ phenotype. The cells were cultured in the presence and absence of hygromycin and/or G418 (Figure 5). After one month, the cells kept in the absence of selective agents or in the presence of G418 alone were more transformed than those kept in the presence of both agents, whereas those exposed to hygromycin alone were completely flat (Figure 5A). Western blot analysis demonstrated that the level of TRK-T3 protein was enhanced by G418 and that of ShcY317F protein was enhanced by hygromycin. Furthermore, the expressions of TRK-T3 and ShcY317F were inversely correlated, and the transformed and flat phenotypes respectively correlated with high expression of TRK-T3 and ShcY317F (Figure 5B). These results confirm the considerations deduced from the focus formation assay in NY317F cells, and indicate that TRK-T3 induced transformation is maintained only if endogenous Shc signalling is preserved.

**DISCUSSION**

TRK oncogenes, associated with a consistent fraction of human papillary thyroid carcinoma, are generated by somatic rearrangements and display constitutive tyrosine kinase activity (Pierotti et al, 1996). The biological effects of rearranged TRK oncogenes recapitulate that of the wild type NTRK1 receptor. In fact, similarly to the activated receptor counterpart, TRK oncogenes induce transformation of NIH3T3 mouse fibroblasts and differentiation of rat pheochromocytoma PC12 cells. Analysis of TRK oncogenes signal transduction, performed in NIH3T3 foci, have detected the involvement of several signal transducers recruited by the NGF-stimulated NTRK1 receptor, such as Shc, PLC, ERK1/2 and JNK MAP kinases (Borrello et al, 1994, manuscript in preparation).

With the aim to understand the mechanism leading to thyroid transformation, we explored the role of the Shc adaptor protein in the signal transduction triggered by TRK-T3 oncogene. The mutation of TRK-T3 tyrosine 291, corresponding to the tyrosine 490 of the NTRK1 receptor, abolished the interaction with both Shc and FRS2 adapter proteins. This led to the abrogation of TRK-T3 induced differentiation and transformation, thus demonstrating that signalling through tyrosine 291 is essential for oncogene activity and it cannot be compensated by possible TRK oncogene-specific signal transduction pathways.

To assess more directly the role of Shc in TRK-T3 activity, we used the ShcY317F mutant, carrying the mutation of the tyrosine 317 which, in addition to tyrosines 239/240, is involved in Grb2 recruitment. The ShcY317F mutant has been shown to exert a dominant-negative effect on the endogenous Shc activity in different contexts. In ErbB2-positive breast cancer cell lines, ShcY317F blocks growth by disrupting cell-cycle progression (Stevenson et al, 1999); in NIH3T3 cells it reduces the RET/PTC2 oncogene transforming activity (Mercalli et al, 2001); in adipocytes it suppresses the IGF-induced proliferation (Boney et al, 2000); moreover, a Shc mutant lacking the CH1 domain that includes Y317, suppresses NIH3T3 transformation induced by the neu oncogene (Li et al, 1999).

The evidence that the ShcY317F mutant is tyrosyl phosphorylated when coexpressed with TRK-T3 indicates that the oncogene targets residues Tyr239/240 of Shc. However, the capability of phosphorylated ShcY317F to interact with Grb2 is reduced with respect to ShcWT. The expression of ShcY317F protein did not affect the capability of TRK-T3 to recruit and activate FRS2. Nevertheless, ShcY317F had an inhibitory effect on TRK-T3 induced differentiation and transformation, thus supporting the hypothesis that Shc signalling through Y317 is indispensible for TRK-T3 activity.

Our data on NIH3T3 transformation showed that such inhibitory effect depends on the relative amount of TRK-T3 and ShcY317F proteins. Indeed, inhibition is more evident by adding hygromycin to the selection medium: this increases the amount of ShcY317F protein, thus producing the greatest competition with endogenous Shc for binding to TRK-T3. ShcY317F produced effect not only on the foci number, but also on their morphology, which was manifest upon isolation: foci arose in the presence of ShcY317F were less transformed, and were named ‘intermediate’. In addition to these short-term effects on transforming activity, a long-term effect was observed in the cell lines expressing both TRK-T3 and ShcY317F proteins selected as foci of ‘intermediate’ phenotype. In most cases the clones underwent cell death, and the surviving population lost the transformed morphology and TRK-T3 oncogene expression. Other clones maintained the transformed morphology and oncogene expression either because the ShcY317F protein was not sufficient to titrate out the wild type or because they compensated the inhibitory effect of ShcY317F by accessory mechanisms. The inhibition of TRK-T3 activity by ShcY317F is therefore related to effects on proliferation and transformation.

In clones undergoing cell death we observed a significant number of apoptotic cells. This finding is in keeping with recent data suggesting that Shc plays a role in promoting cell survival and counteracting apoptosis in response to cytokine receptors (Gu et al, 2000) and NGF receptor (Ulrich et al, 1998; Ashcroft et al, 1999) stimulation. The occurrence of apoptosis in our experimental system can be explained by several hypotheses: (1) Shc might transduce possible TRK-T3 anti-apoptotic signals; (2) signalling through tyrosine 317 of Shc could counteract a possible pro-
apoptotic pathway induced by TRK-T3; (3) a pro-apoptotic signal might be the consequence of cell stress due to incorrectly trans-
duced TRK-T3 signalling. Interestingly, results similar to ours 
have been obtained by co-expressing ShcY317F and the Ret/PTC2 
oncogene (Mercalli et al., 2001), thus indicating the existence of 
a mechanism shared by other RTK oncogenes.

In conclusion, our data demonstrate that signalling through 
ShcY317 is essential for TRK-T3 transformation. This residue 
may cooperate with Tyr239/240 and/or other pathways in such a 
way that, when mutated, the signalling is not sufficient for specific 
endpoints; alternatively, Tyr317 may itself trigger specific pathways. 
Furthermore, the inhibitory effect of ShcY317F may be due to 
competition not only with endogenous Shc, but also with other 
adaptors docking the same TRK-T3 site.

The relevance of these studies is the possibility to block the 
transforming potential of TRK oncogenes by interfering with 
signalling through the Y317 residue of Shc. However, the mechan-
ism responsible for this inhibitory effect, in particular the apoptotic 
process, deserves further investigations.

ACKNOWLEDGEMENTS

This study was supported by the AIRC (Associazione Italiana per la 
Ricerca sul Cancro). The authors would like to thank MG Borrello 
for discussion, S Pagliardini for technical assistance and Cristina 
Mazzadi for her secretarial assistance.
REFERENCES

Ashcroft M, Stephens RM, Hallberg B, Downward J, Kaplan DR (1999) The selective and inducible activation of endogenous PI 3-kinase in PC12 cells result in efficient NGF-mediated survival but defective neurite outgrowth. Oncogene 18: 4586 – 4597

Boney CM, Gruppuso PA, Faris RA, Frackelton Jr AR (2000) The critical role of Shc in insulin-like growth factor-1-mediated mitogenesis and differentiation in 3T3-L1 preadipocytes. Mol Endocrinol 14: 805 – 813

Bongarzone I, Pierotti MA, Monzini N, Mandelli P, Manenti G, Donghi R, Pilotti S, Greco M, Santoro M, Fusco A, Vecchio G, Della Porta G (1989) High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4: 1457 – 1462

Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti MG, Peliggi PG, Pierotti MA (1994) The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Gbeta2 adaptor proteins. Oncogene 9: 1661 – 1668

Canu N, Possenti R, Rinaldi AM, Trani E, Levi A (1997) Molecular cloning and characterization of the human VGF promoter region. J Neurochem 68: 1390 – 1399

Dikic I, Batzer AG, Blakie P, Obermeier A, Ullrich A, Schlessinger J, Margolis B, Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP (1999) Role of tyrosine residues and protein interaction domains of SHC adaptor protein in VEGF receptor 3 signaling. Oncogene 18: 507 – 514

Dikic I, Batzer AG, Blaikie P, Obermeier A, Ullrich A, Schlessinger J, Margolis B (1995) Shc binding to Nerve Growth Factor Receptor Factor is mediated by the phosphotyrosine interaction domain. J Biol Chem 270: 15125 – 15129

Fournier E, Blakie P, Rosnet O, Margolis B, Birnbaum D, Borg JP (1999) Role of tyrosine residues and protein interaction domains of SHC adaptor protein in VEGF receptor 3 signaling. Oncogene 18: 507 – 514

Gotoh N, Toyo A, Shibuya M (1996) A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3. EMBIO J 15: 6197 – 6204

Gotoh N, Toyoda M, Shibuya M (1997) Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation. Mol Cell Biol 17: 1823 – 1831

Greco A, Fusetti L, Miranda C, Villa R, Zanotti S, Pagliardini S, Pierotti MA (1998) Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene 16: 809 – 816

Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M, Pierotti MA (1995) The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol 15: 6118 – 6127

Gu H, Maeda H, Moon JJ, Lornd JD, Yoakim M, Nelson BH, Neel BG (2000) New role for Shc activation of the phosphatidylinositol-3-kinase/akt pathway. Mol Cell Biol 20: 7109 – 7120

Kaplan DR, Miller FD (1997) Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol 9: 213 – 221

Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, Schlessinger J (1997) A lipid-anchored Grb2-binding protein that links FGFR-receptor activation to the Ras/MAPK signaling pathway. Cell 89: 693 – 702

Li K, Shao R, Hung MC (1999) Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway. Oncogene 18: 2617 – 2626

MacDonald IJS, Gryz EA, Kubu CJ, Verdi JM, Meakin SO (2000) Direct binding of the signaling adapter protein grb2 to the activation loop tyrosines on the nerve growth factor receptor tyrosine kinase, trkA. J Biol Chem 275: 18225 – 18233

Meakin SO, MacDonald IJS, Gryz EA, Kubu CJ, Verdi JM (1999) The signal-adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation. J Biol Chem 274: 9861 – 9870

Mencinger M, Aman P (1997) Characterization of TFG in mus musculus and Caenorhabditis elegans. Biochem Biophys Res Commun 257: 67 – 73

Mencinger M, Panagopoulos I, Andresson P, Lassen C, Mitelman F, Aman P (1997) Characterization and chromosomal mapping of the human TFG gene involved in thyroid carcinoma. Genomics 41: 372 – 331

Mercalli E, Ghizzoni S, Arighi E, Alberta L, Sangregorio R, Radice MT, Ghizzky ML, Pierotti MA, Borrello MG (2001) Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein. Oncogene 20: 3475 – 3485

Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG (1999) The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402: 309 – 313

Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superfib-Furga G, Pawson T, Di Fiore PP, Lanfrancone L, Pelicci PG (1997) Opposite effects of the p52shc/p66shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fox signalling pathway. EMBO J 16: 706 – 716

Miranda C, Greco A, Miele C, Pierotti MA, Van Obberghen E (2001) IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1. J Cell Physiol 186: 35 – 46

Moragaki Y, Chou TT, Kaplan DR, Trojanowski QJ, Lee VM (1997) Nerve growth factor induces apoptosis in human medulloblastoma cell lines that express TrkA receptors. J Neurosci 17: 530 – 542

Obermeier A, Lamers R, Wiesmuller KH, Jung G, Schlessinger J, Ullrich A (1993) Identification of Trk binding sites for SHC and phosphatidylinositol-3′-kinase and formation of a multimeric signaling complex. J Biol Chem 268: 22963 – 22966

Ong SH, Guy GR, Hadari YR, Laks S, Gotoh N, Schlessinger J, Lax I (2000) FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol 20: 979 – 989

Pelicci G, Lanfrancone L, Grignani F, McClade J, Cavallo F, Forini G, Nicoletti I, Pawson T, Pelicci PG (1992) A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70: 93 – 104

Pierotti MA, Bongarzone I, Borrello MG, Greco A, Pilotti S, Sozzi G (1996) Cytogenetics and molecular genetics of the carcinomas arising from the thyroid epithelial follicular cells. Genes Chrom Cancer 16: 1 – 14

Possenti R, Di Rocco G, Nasi S, Levi A (1992) Regulatory elements in the promoter region of vgf, a nerve growth factor-inducible gene. Proc Natl Acad Sci USA 89: 3815 – 3819

Qian X, Riccio A, Zhang Y, Giunti DD (1998) Identification and characterization of novel substrates of Trk receptors in developing neurons. Neuron 21: 1017 – 1029

Rabin SJ, Cleghorn V, Kaplan DR (1993) SNT, a differentiation-specific target of neurotrophic factor-induced tyrosine kinase activity in neurons and PC12 cells. Mol Cell Biol 13: 2203 – 2213

Stephens RM, Loeb DM, Copeland TD, Pawson T, Greene LA, Kaplan DR (1994) Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma1 to mediate NGF responses. Neuron 12: 691 – 705

Stevenson LE, Ravichandran KS, Frackelton AR Jr (1999) Shc dominant negative disrupts cell cycle progression in both G0-G1 and G2-M of ErbB2-positive breast cancer cells. Cell Growth Diff 10: 61 – 71

Thomas D, Bradshaw RA (1997) Differential utilization of ShcA tyrosine residues and functional domains in the transduction of epidermal growth factor-induced mitogenic-activated protein kinase activation in 293T cells and nerve growth factor-induced neurite outgrowth in PC12 cells. Identification of a new Grb2.Sos1 binding site. J Biol Chem 272: 22293 – 22299

Ullrich E, Duwel A, Kaufmann-Zeh A, Gilbert C, Lyon D, Rudkin B, Egan V, Martin-Zanca D (1998) Specific TrkA survival signals interfere with different apoptotic pathways. Oncogene 16: 825 – 832

Van der Geer P, Wiley S, Lai KV, Olivier JP, Gish GD, Stephens R, Kaplan D, Shoelson S, Pawson T (1995) A conserved amino-terminal Shc domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides. Curr Biol 5: 404 – 412